1-13 of 13
Malcolm J. Moore
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials

Joao Paulo Solar Vasconcelos, Nan Chen, Emma Titmuss, Dongsheng Tu, Stephanie Y. Brule, Rachel Goodwin, Derek J. Jonker, Timothy Price, John R. Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Lillian Siu, Jeremy Shapiro, John Simes, Sharlene Gill, Chris J. O'Callaghan, Jonathan M. Loree
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1121–1130.
https://doi.org/10.1158/1078-0432.CCR-23-3275
Published: 15 March 2024
View article titled, Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
Open the PDF for Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial

Jonathan M. Loree, Anthony Dowers, Dongsheng Tu, Derek J. Jonker, Daniel L. Edelstein, Hannah Quinn, Frank Holtrup, Timothy Price, John R. Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Chris J. O'Callaghan, Paul Waring, Hagen F. Kennecke, Stanley R. Hamilton, Scott Kopetz
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 52–59.
https://doi.org/10.1158/1078-0432.CCR-20-2710
Published: 04 January 2021
View article titled, Expanded Low Allele Frequency <em>RAS</em> and <em>BRAF</em> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
Open the PDF for Expanded Low Allele Frequency <em>RAS</em> and <em>BRAF</em> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial in another window
Includes: Supplementary data
Journal Articles

Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer

Joanna M. Karasinska, James T. Topham, Steve E. Kalloger, Gun Ho Jang, Robert E. Denroche, Luka Culibrk, Laura M. Williamson, Hui-Li Wong, Michael K.C. Lee, Grainne M. O'Kane, Richard A. Moore, Andrew J. Mungall, Malcolm J. Moore, Cassia Warren, Andrew Metcalfe, Faiyaz Notta, Jennifer J. Knox, Steven Gallinger, Janessa Laskin, Marco A. Marra, Steven J.M. Jones, Daniel J. Renouf, David F. Schaeffer
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 135–146.
https://doi.org/10.1158/1078-0432.CCR-19-1543
Published: 03 January 2020
View article titled, Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer
Open the PDF for Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma

Martin R. Jones, Laura M. Williamson, James T. Topham, Michael K.C. Lee, Angela Goytain, Julie Ho, Robert E. Denroche, GunHo Jang, Erin Pleasance, Yaoquing Shen, Joanna M. Karasinska, John P. McGhie, Sharlene Gill, Howard J. Lim, Malcolm J. Moore, Hui-li Wong, Tony Ng, Stephen Yip, Wei Zhang, Sara Sadeghi, Carolyn Reisle, Andrew J. Mungall, Karen L. Mungall, Richard A. Moore, Yussanne Ma, Jennifer J. Knox, Steven Gallinger, Janessa Laskin, Marco A. Marra, David F. Schaeffer, Steven J.M. Jones, Daniel J. Renouf
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4674–4681.
https://doi.org/10.1158/1078-0432.CCR-19-0191
Published: 01 August 2019
View article titled, <em>NRG1</em> Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in <em>KRAS</em> Wild-Type Pancreatic Ductal Adenocarcinoma
Open the PDF for <em>NRG1</em> Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in <em>KRAS</em> Wild-Type Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial

Kyaw L. Aung, Sandra E. Fischer, Robert E. Denroche, Gun-Ho Jang, Anna Dodd, Sean Creighton, Bernadette Southwood, Sheng-Ben Liang, Dianne Chadwick, Amy Zhang, Grainne M. O'Kane, Hamzeh Albaba, Shari Moura, Robert C. Grant, Jessica K. Miller, Faridah Mbabaali, Danielle Pasternack, Ilinca M. Lungu, John M.S. Bartlett, Sangeet Ghai, Mathieu Lemire, Spring Holter, Ashton A. Connor, Richard A. Moffitt, Jen Jen Yeh, Lee Timms, Paul M. Krzyzanowski, Neesha Dhani, David Hedley, Faiyaz Notta, Julie M. Wilson, Malcolm J. Moore, Steven Gallinger, Jennifer J. Knox
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (6): 1344–1354.
https://doi.org/10.1158/1078-0432.CCR-17-2994
Published: 14 March 2018
View article titled, Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
Open the PDF for Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial in another window
Includes: Supplementary data
Journal Articles

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17

Christos S. Karapetis, Derek Jonker, Manijeh Daneshmand, Jennifer E. Hanson, Christopher J. O'Callaghan, Celia Marginean, John R. Zalcberg, John Simes, Malcolm J. Moore, Niall C. Tebbutt, Timothy J. Price, Jeremy D. Shapiro, Nick Pavlakis, Peter Gibbs, Guy A. Van Hazel, Ursula Lee, Rashida Haq, Shakeel Virk, Dongsheng Tu, Ian A.J. Lorimer, for the NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (3): 744–753.
https://doi.org/10.1158/1078-0432.CCR-13-0606
Published: 02 February 2014
View article titled, <em>PIK3CA, BRAF</em>, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
Open the PDF for <em>PIK3CA, BRAF</em>, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17 in another window
Journal Articles

Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer

Patricia A. Tang, Steven J. Cohen, Christian Kollmannsberger, Georg Bjarnason, Kiran Virik, Mary J. MacKenzie, Lillian Lourenco, Lisa Wang, Alice Chen, Malcolm J. Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 6023–6031.
https://doi.org/10.1158/1078-0432.CCR-11-3252
Published: 06 November 2012
View article titled, Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer
Open the PDF for Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Alternate Endpoints for Screening Phase II Studies

Neesha Dhani, Dongsheng Tu, Daniel J. Sargent, Lesley Seymour, Malcolm J. Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 1873–1882.
https://doi.org/10.1158/1078-0432.CCR-08-2034
Published: 16 March 2009
View article titled, Alternate Endpoints for Screening Phase II Studies
Open the PDF for Alternate Endpoints for Screening Phase II Studies in another window
Journal Articles

Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination

Carol A. Townsley, Gregory R. Pond, Amit M. Oza, Hal W. Hirte, Eric Winquist, Glenwood Goss, Pamela Degendorfer, Malcolm J. Moore, Lillian L. Siu
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 2141–2149.
https://doi.org/10.1158/1078-0432.CCR-05-1798
Published: 11 April 2006
View article titled, Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination
Open the PDF for Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination in another window
Journal Articles

Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue

Carlton K. K. Lee, Eric K. Rowinsky, Jing Li, Francis Giles, Malcolm J. Moore, Manuel Hidalgo, Edmund Capparelli, Jacques Jolivet, Sharyn D. Baker
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 2158–2165.
https://doi.org/10.1158/1078-0432.CCR-05-2249
Published: 11 April 2006
View article titled, Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue
Open the PDF for Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue in another window
Journal Articles

Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

Lillian L. Siu, Ahmad Awada, Chris H. Takimoto, Martine Piccart, Brian Schwartz, Tom Giannaris, Chetan Lathia, Oana Petrenciuc, Malcolm J. Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (1): 144–151.
https://doi.org/10.1158/1078-0432.CCR-05-1571
Published: 05 January 2006
View article titled, Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer
Open the PDF for Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer in another window
Journal Articles

Pharmacological Determinants of 9-Aminocamptothecin Cytotoxicity

Mei-Li Li, Leora Horn, Patricia S. Firby, Malcolm J. Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (1): 168–174.
Published: 01 January 2001
View article titled, Pharmacological Determinants of 9-Aminocamptothecin Cytotoxicity
Open the PDF for Pharmacological Determinants of 9-Aminocamptothecin Cytotoxicity in another window
Journal Articles

Differential Sensitivity of Various Pediatric Cancers and Squamous Cell Carcinomas to Lovastatin-induced Apoptosis: Therapeutic Implications

Jim Dimitroulakos, Lily Y. Ye, Mark Benzaquen, Malcolm J. Moore, Suzanne Kamel-Reid, Melvin H. Freedman, Herman Yeger, Linda Z. Penn
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (1): 158–167.
Published: 01 January 2001
View article titled, Differential Sensitivity of Various Pediatric Cancers and Squamous Cell Carcinomas to Lovastatin-induced Apoptosis: Therapeutic Implications
Open the PDF for Differential Sensitivity of Various Pediatric Cancers and Squamous Cell Carcinomas to Lovastatin-induced Apoptosis: Therapeutic Implications in another window